{
  "id": 14572504,
  "title": "Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1",
  "url": "https://urgent.news/2026/10/15/takedas-orzeyful-oveporexton-launches-simultaneously-in-japan-and",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-15T00:40:05.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/takedas-orzeyful-oveporexton-launches-simultaneously-in-japan-and-china-giving-physicians-first-access-to-prescribe-novel-orexin-agonist-to-patients-with-narcolepsy-type-1"
  },
  "original_language": "en",
  "account": null,
  "summary": "− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}